Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series
The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of bone, but the available data in the literature remains sparse and controversial. This study analyzes the results o...
Citation: World Journal of Surgical Oncology 2016 14:281